Synairgen shares stay tradeable post-delisting, as top investor waives restrictions
Synairgen PLC (AIM:SNG, OTC:SYGGF), a biotech company developing an experimental inhaled treatment for respiratory infections, says its shares will remain...…
£0,009
-14,85%
Echtzeit-Aktienkurs Synairgen PLC
Bid:
Ask:
Nachrichten zur Synairgen PLC Aktie
AIM movers: Solid State wins contract and Synairgen set to leave junior market
North Sea oil and gas explorer Deltic Energy (LON: DELT) has revised its internal economic model for the development of…
Synairgen becomes the latest company to eye the AIM exit door
Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London’s AIM market…
Synairgen CEO on funding phase 2 trial for SNG001
Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the companys recent fundraising efforts to support a…
Synairgen CEO on funding phase 2 trial for SNG001
Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the companys recent fundraising efforts to support a…
AIM movers: Tiger technology move and Synairgen fundraising
Tiger Royalties and Investments (LON: TIR) is changing strategy to become a technology incubator. It is acquiring Bixby Technology Inc,…
Synairgen CEO on funding critical Phase 2 trial for SNG001
…
Synairgen backer ready to pump £18-£19 million into phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £25 million to fund the...…
Synairgen makes progress in H1 as it moves towards phase II trial of lead asset
…
Synairgen making substantial progress towards phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made substantial progress preparing for a phase II trial of its lead asset,…
Synairgen appoints inhaled drug development expert as chairman
Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next months annual shareholder meeting, to be replaced by Mark…
Synairgen provides update on progress during 2023
…
Synairgen making plans for phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe…